Nicholas Lydon, Director at Blueprint Medicines Corp (BPMC), sold 19,630 shares at $93.68 ($1.8M) on 2020-10-01, disclosed to the SEC on 2020-10-05.
Open-market sale of $1.8M BPMC by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $92.06 | 1,389 | $128K | 7.0% |
| 2 | $92.06 | 1,389 | $128K | 7.0% |
| 3 | $92.88 | 4,530 | $421K | 23.0% |
| 4 | $92.88 | 4,530 | $421K | 23.0% |
| 5 | $93.68 | 3,896 | $365K | 20.0% |
| 6 | $93.68 | 3,896 |
| $365K |
| 20.0% |
| Total | $93.08 avg | 19,630 | $1.8M | 100% |
| Filing → |
| BPMC | SELL | 2020-07-06 | $661K | — | Filing → |
| BPMC | SELL | 2020-06-25 | $32K | — | Filing → |
| BPMC | SELL | 2020-06-23 | $2.1M | — | Filing → |